Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care
Summary
- Immunosuppressants concentrations may be increased with coadministration of PIs, cobicistat/elvitegravir/emtricitabine/tenofovir DF, or cobicistat/elvitegravir/emtricitabine/tenofovir AF and decreased with NNRTIs
- Starting the immunosuppressant at a lower dose when administered with PIs, cobicistat/elvitegravir/emtricitabine/tenofovir DF, or cobicistat/elvitegravir/emtricitabine/tenofovir AF, and a higher dose with NNRTIs is recommended, using therapeutic drug monitoring and monitoring closely for toxicities[DHHS ART]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Drug-Drug Interactions, Pharmacokinetics